author-photo

V. Breder

21

Papers

1831

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.

2021 The Lancet Gastroenterology & Hepatology
Show All
- Source
- Cite
- Save
Citations (3)
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib

2018 Zeitschrift Fur Gastroenterologie
Show All
- Source
- Cite
- Save
Citations (0)
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (32)
O-009Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
113PClinical outcomes and quality of life (QoL) in adults with advanced refractory non-small cell lung cancer (NSCLC) patients receiving nivolumab (Nivo) as 2+ line treatment: Interim analysis of expanded access program

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment

2017 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (12)
Observational study of the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

2017 The Lancet
Show All
- Source
- Cite
- Save
Citations (1725)